Press Releases and Blog
Blog
PCMA Urges CMS to Stabilize the Medicare Part D Plan Marketplace
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association Last week, PCMA offered recommendations to the Centers for Medicare and Medicaid Services
CMS Should Protect the Financial Health of Pharmacies When Implementing the IRA
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association If the community pharmacy lobby is right, America’s Medicare beneficiaries may not be
JC Scott: When Will Drug Companies Answer the Call to Lower Egregious Drug Prices?
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), wrote an op-ed in D.C. Journal calling on
Axios: PhRMA “Laser-Focused” On Lame Duck PBM Bills
Undermining PBM Cost Saving Tools Gives Big Pharma Windfall Profits Axios recently reported on Big Pharma’s number one Lame Duck priority: Proposals undermining pharmacy benefit
Comprehensive Analysis Of PBMs From Prominent Economists Confirm Value of PBMs, Dispel FTC Findings
An important new economic analysis contradicts the findings of a recent Federal Trade Commission (FTC) interim staff report. Dennis W. Carlton, Ph.D., David McDaniel Keller
ICYMI: Experts from Competitive Enterprise Institute and Mercatus Center Highlight Fundamental Flaws in FTC PBM Suit
In case you missed it, the growing consensus surrounding the recent actions from the Federal Trade Commission (FTC), including releasing an interim staff report on
Press Releases
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement today: “The industry trade association representing America’s pharmacy benefit companies reiterates its position that, to date, the Federal Trade Commission (FTC) has fallen far short of providing a definitive, fact-based assessment of pharmacy benefit managers (PBMs) or the […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the U.S. House Committee on the Judiciary Subcommittee on the Administrative State, Regulatory Reform, and Antitrust hearing. “We urge the House Judiciary Subcommittee to focus on the root cause of the prescription drug pricing problem: Egregious patent abuse by some drug […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that RxBenefits is joining the trade association as its newest member. “PCMA is proud to represent the pharmacy benefit industry, and the addition of RxBenefits to our membership once again showcases the diversity of pharmacy benefit companies and the variety of offerings available to employers and health plans […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement following the Biden Administration’s announcement of the first ten Medicare negotiated drug prices: “While we share the Administration’s goal to reduce prescription drug costs for America’s seniors and to push back against the high prices set by drug manufacturers, the Administration has […]
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of the U.S. House Committee on Oversight and Accountability hearing, “The Role of Pharmacy Benefit Managers in Prescription Drug Markets Part III: Transparency and Accountability,” on pharmacy benefit managers (PBMs). “We encourage the U.S. House Oversight Committee lawmakers to engage in a […]
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement today following the U.S. Senate’s passage of legislation sponsored by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT) aimed at increasing competition in the prescription drug market. “PCMA applauds the Senate’s action to advance this critical bipartisan legislation to end anti-competitive practices, such […]
Patient Access and Insulin: Market Forces, Innovative PBM Programs Lowering Costs for Patients
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies
Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO
Economists Ike Brannon and Anthony Lo Sasso: The Real Challenge Facing Independent Pharmacies
As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would
What They Are Saying: PBMs Help Businesses, Families, And Patients Save On Rx Costs, Allow Employers To Offer Competitive Benefits
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically
Pharmacy Benefit Companies Partner To Support Rural Pharmacies And Patients
This week, community pharmacists will conduct a “Fly-In” in Washington D.C. Undoubtedly, part of the message to Congress will be critical of pharmacy benefit companies,
RealClearMarkets Op-Ed: “Attacks On Pharmacy Benefit Managers Won’t Reduce Drug Prices”
As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of
PBMs Support Competition and Innovation to Lower Prescription Drug Costs
The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the
Matrix Global Advisors Touts Biosimilar Interchangeability Proposal in Biden Administration Budget – SSR Health: Biosimilar Competition Leads to Significant Decline in Net Prices on Brand Humira
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
